Danish Registry Analysis Finds Consistent Safety After Switching to Infliximab Biosimilar GP1111

February 03, 2026

New Danish registry data confirm the safety of switching to infliximab biosimilars, showing low rates of serious adverse events in patients with inflammatory arthritis.

Q&A With Chelsee Jensen, PharmD: FDA Policy Shifts, Biosimilar Development Hurdles, and Market Access in 2026

February 02, 2026

Early Evidence Supports KM118 as a Biosimilar to Reference Pertuzumab

January 28, 2026

Milestone Approvals, Evolving PBM Models May Redefine the 2026 Biosimilar Landscape

January 27, 2026

FDA Draft Guidance on Biosimilars Is a Win for Patients; Now Congress Must Finish the Job

January 26, 2026

Real-World Evidence Supports Biosimilar HLX02 in Metastatic Breast Cancer

September 11th 2025

By Skylar Jeremias

Article

HLX02 shows promise as a safe, effective trastuzumab biosimilar for HER2-positive metastatic breast cancer, enhancing treatment access and affordability.

Australian Study Reveals Significant Cost Savings and Market Impact From Biosimilars

September 10th 2025

By Skylar Jeremias

Article

Biosimilars significantly reduce health care costs in Australia, enhancing access to biologics while driving price competition in the pharmaceutical market.

Switch to Biosimilar Adalimumab Found Safe and Cost-Saving for Patients With IBD

September 9th 2025

By Skylar Jeremias

Article

A study reveals that switching from Humira to Amgevita for IBD maintains disease control and offers significant cost savings.

SYSA1902 Biosimilar Proves Equivalent to Reference Ustekinumab in Plaque Psoriasis

September 8th 2025

By Skylar Jeremias

Article

A new biosimilar, SYSA1902, shows comparable efficacy and safety to ustekinumab for treating moderate-to-severe plaque psoriasis, expanding patient options.

The Top 5 Biosimilar Articles for the Week of September 1

September 5th 2025

By Skylar Jeremias

Video

Here are the top 5 biosimilar articles for the week of September 1, 2025.

Japanese Trial Supports Widespread Use, Safety of Infliximab Biosimilar Use

September 4th 2025

By Skylar Jeremias

Article

A recent Japanese study confirms that switching from originator infliximab to biosimilars maintains remission in patients who have rheumatoid arthritis, enhancing treatment accessibility.

Patients With nAMD Maintain Vision on Aflibercept Biosimilar ABP 938

September 3rd 2025

By Skylar Jeremias

Article

A new biosimilar for aflibercept shows similar efficacy and safety in treating neovascular age-related macular degeneration (nAMD), enhancing patient access to treatment.

Biosimilars News Roundup: August 2025

September 2nd 2025

By Skylar Jeremias

Article

August 2025 brought significant advancements in biosimilars, including financial successes, new product launches, and research on ongoing challenges in market access.

FDA Greenlights Fifth Pair of Denosumab Biosimilars: Bildyos and Bilprevda

September 2nd 2025

By Skylar Jeremias

Article

New denosumab biosimilars, Bildyos and Bilprevda, enhance access to affordable osteoporosis and bone disease treatments, promising significant patient benefits.

The Top 5 Biosimilar Articles for the Week of August 25

August 29th 2025

By Skylar Jeremias

Video

Here are the top 5 biosimilar articles for the week of August 25, 2025.